HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: dc07-1378v1 31/2/210    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Weinzimer, S. A. Search for Related Content PubMed PubMed Citation Articles by Weinzimer, S. A. Social Bookmarking                What's this?

A Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion of Insulin Aspart versus Insulin Lispro in Children and Adolescents with Type 1 Diabetes

¹Yale University School of Medicine, New Haven, Connecticut
²University of Minnesota Physicians, Minneapolis, Minnesota
³Novo Nordisk Inc., Princeton, New Jersey
⁴Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
⁵Joslin Diabetes Center, Boston, Massachusetts

stuart.weinzimer{at}yale.edu

ABSTRACT

Objective: The safety and efficacy of insulin aspart in continuous subcutaneous insulin infusion (CSII) was compared to that of insulin lispro CSII in children and adolescents with type 1 diabetes.

Research Design and Methods: Children and adolescents 4-18 years of age with diagnosed type 1 diabetes 1 year previously treated with insulin analog CSII 3 months were randomized 2:1 to 16 weeks of insulin aspart CSII (n=198) or insulin lispro CSII (n=100) in this open-label, parallel-group, multicenter study. Standard diabetes safety and efficacy parameters were assessed.

Results: Baseline demographics, subject characteristics, and diabetes history were similar between treatment groups. After 16 weeks of treatment, insulin aspart CSII was non-inferior to insulin lispro CSII as measured by change in HbA_1c from baseline (aspart, –0.15±0.05%; lispro, –0.05±0.07%; 95% CI of the treatment difference, [-0.27, 0.07]; p=0.241). No significant differences between treatment groups were observed in fasting plasma glucose (FPG), hyperglycemia, and rates of hypoglycemic episodes. At Week 16, 59.7% of subjects in the aspart group and 43.8% of subjects in the lispro groups achieved age-specific ADA HbA_1c goals (<8.5% for subjects < 6 years; <8% for subjects 6-18 years) (p=0.040, corrected for baseline). Daily insulin dose (U/kg) was significantly lower at Week 16 for subjects treated with aspart, as compared to those treated with lispro (0.86±0.237 vs. 0.94±0.233, p=0.018).

Conclusions: Insulin aspart was as safe and effective as insulin lispro for use in CSII in children and adolescents with type 1 diabetes.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?